Incepta launches first resmetirom medicine in Bangladesh
Liver diseases, particularly fatty liver and Metabolically Dysregulated Associated Steatohepatitis (MASH), are emerging as major public health challenges in Bangladesh.
In a development for patients suffering from these conditions, Incepta Pharmaceuticals has introduced a new medicine, under the brand name "Frehepta" (generic: Resmetirom), for the treatment of fatty liver and MASH. This is the first time the medicine has been launched in Bangladesh.
Globally, Resmetirom has been recognised as a significant advancement in the management of fatty liver and MASH. Clinical studies have shown that the drug can reduce liver fat, improve fibrosis markers, and is associated with a lower risk of adverse effects compared to existing treatment options.
Keep updated, follow The Business Standard's Google news channel
Incepta Pharmaceuticals has made the medicine available at a more affordable price in the local market. The company emphasised that Frehepta must be used only on the prescription of a registered physician.
